Norway

On 19 October 2026, the Norwegian Directorate of Health published the preliminary 2027 activity-based funding (ISF) framework, including updates to the Diagnosis-Related Group (DRG) system. While the overall system remains largely unchanged, the share of activity-based funding for somatic specialist care is set to increase from 30% to 40%. Seven new DRGs and four Special Service Groups (STGs) are planned, although none of them are directly related to MedTech.

On 7 October 2026, the Norwegian Directorate of Health released the 2027 Norwegian Clinical Procedure Coding system (NKPK), introducing 23 new procedure codes across medical, surgical and radiological specialties. The additions cover areas including eHealth, neuromodulation, endoscopy, gastrointestinal procedures, dermatology and gynecology. Several existing codes have also been revised, while six have been discontinued. The changes will take effect on 1 January 2027.

In September 2026, the Norwegian Directorate of Health released an updated version of the Norwegian Laboratory Code (NLK) system, introducing 114 new codes across medical biochemistry, microbiology, genetics, clinical pharmacology, and immunology. The regular update reflects changes in laboratory practice and ensures that the coding and reimbursement infrastructure continues to accommodate new and evolving diagnostic tests.

Since June 2026, seven new mini-HTAs have been initiated in Norway, including two MedTech-related assessments in the in vitro diagnostics and cardiovascular areas. These assessments are conducted as part of Norway’s framework for the managed introduction of innovations, known as “New Methods”.

On August 26, 2026, New Nordics AI launched the Nordic AI Health Map, a collaborative mapping of artificial intelligence initiatives in publicly financed healthcare across Denmark, Finland, Iceland, Norway, and Sweden. The map provides an interactive overview of how AI is being developed and used in Nordic healthcare – from early-stage concepts and pilots to solutions integrated into everyday clinical practice.

Between January 1 and June 1, 2026, seven MedTech-related mini-HTAs were initiated in Norway across orthopedics, neurology and rehabilitation, in vitro diagnostics, interventional radiology, diagnostic imaging, and e-health. These assessments are conducted as part of Norway’s framework for the managed introduction of innovations, known as “New Methods”.

On May 18, 2026, the Decision Forum for “New Methods” updated its coverage decision for molecular gene profile analysis using Oncotype DX. The test, which has been covered since 2024 for postmenopausal patients with lymph node-positive HR-positive, HER2-negative, early-stage invasive breast cancer, will now also be covered for patients with lymph node-negative breast cancer.

On May 22, 2026, the Norwegian Directorate of Health released an updated version (v.80) of the Norwegian Laboratory Code (NLK) system, along with associated tariffs, for both state and private laboratories. A total of 23 new codes were added in the biochemistry, microbiology, and immunology fields.

On May 1, 2026, a new process for handling medical devices (including in vitro diagnostics and AI-based devices) within the Norwegian “New Methods” framework entered into force. Three entry pathways into the framework were implemented, including through manufacturer requests. Selection criteria were clarified to define which devices must be considered within the framework.

In late March 2026, Norway’s “New Methods” framework announced a revised process for managing medical technologies (i.e., medical devices, in-vitro diagnostics, procedures), effective May 1, 2026. The update introduces new entry pathways, application process, prioritization criteria, and procedural changes such as early assessment and implementation meetings. Medical device companies are invited to a digital information session on April 17, 2026, with registration required by April 14, 2026.

On March 23, 2026, the Norwegian Directorate of Health released an updated version (v.79) of the Norwegian Laboratory Code (NLK) system, along with associated tariffs, for both state and private laboratories. A total of 63 new codes were added in the biochemistry, microbiology, clinical pharmacology, and immunology fields.

In March 2026, the Decision Forum for the "New Methods" framework made a favorable coverage decision for intermittent negative pressure therapy (FlowOx) for conditions related to reduced blood circulation in the extremities